This strategy produces a steady stream of income that exceeds what you can earn from bonds, with less risk. Read More

Merck has been a money-making machine for decades, but it faces growing competition and patent expirations. Will this drug giant prevail? Read More

Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

Is Geron a small-cap stock poised to breakout? Or will this clinical stage biotech run out of cash before its novel drugs can hit the market? Read More